BRAF and melanoma: In 2020, Dummer et al. [36] reported the results of the phase III COMBI-AD trial, in which patients who had resected stage III melanoma with BRAF V600E or V600K mutations were randomly assigned to receive dabrafenib plus trametinib or placebo.